Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 25.98
INCY's Cash-to-Debt is ranked lower than
52% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. INCY: 25.98 )
Ranked among companies with meaningful Cash-to-Debt only.
INCY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.35  Med: 1.41 Max: No Debt
Current: 25.98
Equity-to-Asset 0.63
INCY's Equity-to-Asset is ranked lower than
55% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INCY: 0.63 )
Ranked among companies with meaningful Equity-to-Asset only.
INCY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.83  Med: 0.2 Max: 0.92
Current: 0.63
-1.83
0.92
Debt-to-Equity 0.02
INCY's Debt-to-Equity is ranked higher than
92% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. INCY: 0.02 )
Ranked among companies with meaningful Debt-to-Equity only.
INCY' s Debt-to-Equity Range Over the Past 10 Years
Min: -17.62  Med: 0 Max: 97.27
Current: 0.02
-17.62
97.27
Debt-to-EBITDA -0.32
INCY's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. INCY: -0.32 )
Ranked among companies with meaningful Debt-to-EBITDA only.
INCY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -44.14  Med: 0.24 Max: 17.01
Current: -0.32
-44.14
17.01
Piotroski F-Score: 3
Altman Z-Score: 22.89
Beneish M-Score: -2.54
WACC vs ROIC
11.08%
-15.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -4.73
INCY's Operating Margin % is ranked higher than
69% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. INCY: -4.73 )
Ranked among companies with meaningful Operating Margin % only.
INCY' s Operating Margin % Range Over the Past 10 Years
Min: -4064.53  Med: -2.74 Max: 13.11
Current: -4.73
-4064.53
13.11
Net Margin % -11.77
INCY's Net Margin % is ranked higher than
65% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. INCY: -11.77 )
Ranked among companies with meaningful Net Margin % only.
INCY' s Net Margin % Range Over the Past 10 Years
Min: -4565.45  Med: -21.09 Max: 9.43
Current: -11.77
-4565.45
9.43
ROE % -24.98
INCY's ROE % is ranked higher than
59% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. INCY: -24.98 )
Ranked among companies with meaningful ROE % only.
INCY' s ROE % Range Over the Past 10 Years
Min: -24.98  Med: 24.94 Max: 35.29
Current: -24.98
-24.98
35.29
ROA % -9.80
INCY's ROA % is ranked higher than
69% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. INCY: -9.80 )
Ranked among companies with meaningful ROA % only.
INCY' s ROA % Range Over the Past 10 Years
Min: -70.43  Med: -15.38 Max: 7.88
Current: -9.8
-70.43
7.88
ROC (Joel Greenblatt) % -76.97
INCY's ROC (Joel Greenblatt) % is ranked higher than
65% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. INCY: -76.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INCY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4727.38  Med: -134.72 Max: 115.22
Current: -76.97
-4727.38
115.22
3-Year Revenue Growth Rate 33.50
INCY's 3-Year Revenue Growth Rate is ranked higher than
82% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. INCY: 33.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INCY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.4  Med: 21.9 Max: 523.4
Current: 33.5
-61.4
523.4
GuruFocus has detected 2 Warning Signs with Incyte Corp INCY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INCY's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

INCY Guru Trades in Q3 2016

John Burbank 243,396 sh (New)
Pioneer Investments 80,822 sh (New)
Jana Partners 58,385 sh (New)
Andreas Halvorsen 503,645 sh (New)
Steven Cohen 68,000 sh (New)
Ken Fisher 14,917 sh (+0.67%)
Vanguard Health Care Fund 16,227,748 sh (unchged)
Frank Sands 4,124,074 sh (-7.68%)
Joel Greenblatt 108,099 sh (-24.20%)
George Soros 5,200 sh (-30.67%)
Jim Simons 62,900 sh (-61.78%)
Paul Tudor Jones 10,933 sh (-86.57%)
Eaton Vance Worldwide Health Sciences Fund 237,999 sh (-34.60%)
» More
Q4 2016

INCY Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 91,970 sh (New)
Pioneer Investments 623,117 sh (+670.97%)
Steven Cohen 438,801 sh (+545.30%)
Jana Partners 86,616 sh (+48.35%)
Andreas Halvorsen 730,452 sh (+45.03%)
Ken Fisher 14,917 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Frank Sands 3,652,652 sh (-11.43%)
Vanguard Health Care Fund 11,635,908 sh (-28.30%)
Joel Greenblatt 59,202 sh (-45.23%)
Paul Tudor Jones 4,203 sh (-61.56%)
John Burbank 63,593 sh (-73.87%)
Eaton Vance Worldwide Health Sciences Fund 228,436 sh (-4.02%)
» More
Q1 2017

INCY Guru Trades in Q1 2017

Jeremy Grantham 1,500 sh (New)
Frank Sands 4,250,593 sh (+16.37%)
Ken Fisher 15,050 sh (+0.89%)
Jana Partners Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments 561,063 sh (-9.96%)
Joel Greenblatt 51,406 sh (-13.17%)
Vanguard Health Care Fund 9,256,598 sh (-20.45%)
Manning & Napier Advisors, Inc 55,375 sh (-39.79%)
Andreas Halvorsen 433,978 sh (-40.59%)
John Burbank 19,983 sh (-68.58%)
Steven Cohen 14,600 sh (-96.67%)
Eaton Vance Worldwide Health Sciences Fund 198,561 sh (-13.08%)
» More
Q2 2017

INCY Guru Trades in Q2 2017

Mario Gabelli 2,600 sh (New)
Ron Baron 10,597 sh (New)
Frank Sands 7,983,826 sh (+87.83%)
Joel Greenblatt 70,454 sh (+37.05%)
Steven Cohen 20,000 sh (+36.99%)
Ken Fisher 15,532 sh (+3.20%)
Vanguard Health Care Fund 9,265,098 sh (+0.09%)
John Burbank Sold Out
Jeremy Grantham Sold Out
Manning & Napier Advisors, Inc Sold Out
Andreas Halvorsen Sold Out
Pioneer Investments 458,888 sh (-18.21%)
Eaton Vance Worldwide Health Sciences Fund 176,462 sh (-11.13%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Add 0.09%$115.19 - $141.55 $ 114.19-10%9,265,098
Joel Greenblatt 2017-06-30 Add 37.05%0.03%$115.19 - $141.55 $ 114.19-10%70,454
Ken Fisher 2017-06-30 Add 3.20%$115.19 - $141.55 $ 114.19-10%15,532
Ron Baron 2017-06-30 New Buy0.01%$115.19 - $141.55 $ 114.19-10%10,597
Mario Gabelli 2017-06-30 New Buy$115.19 - $141.55 $ 114.19-10%2,600
Vanguard Health Care Fund 2017-03-31 Reduce -20.45%0.57%$102.32 - $152.66 $ 114.19-10%9,256,598
Joel Greenblatt 2017-03-31 Reduce -13.17%0.01%$102.32 - $152.66 $ 114.19-10%51,406
Ken Fisher 2017-03-31 Add 0.89%$102.32 - $152.66 $ 114.19-10%15,050
Vanguard Health Care Fund 2016-12-31 Reduce -28.30%0.94%$83.28 - $108.1 $ 114.1917%11,635,908
Joel Greenblatt 2016-12-31 Reduce -45.23%0.06%$83.28 - $108.1 $ 114.1917%59,202
George Soros 2016-12-31 Sold Out 0.02%$83.28 - $108.1 $ 114.1917%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:XKRX:207940, XMCE:GRF.P, XSWX:ATLN, NAS:BMRN, XKRX:068270, NAS:ALXN, SZSE:002252, OCSE:NZYM B, OCSE:GEN, XBRU:UCB, NAS:ALNY, NAS:KITE, NAS:VRTX, NAS:JAZZ, NAS:ALKS, HKSE:01177, NAS:SGEN, NAS:EXEL, NAS:TSRO, NAS:IONS » details
Traded in other countries:INCY.Austria, ICY.Germany,
Headquarter Location:USA
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which is licensed by Eli Lilly, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including IDO inhibitor epacadostat and next-generation JAK inhibitor itacitinib.

Top Ranked Articles about Incyte Corp

Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell
Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis
3 Stocks With Strong Movements Wednesday Morning Dycom Industries, AeroVironment and VBI Vaccines among top movers
The U.S. stock market opened lower with the three main indexes in red, but two soon turned green.  Read more...
Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018
2 Stocks Fall on Earnings Report Hain Celestial Group and Best Buy decline despite beating estimates
The U.S. stock market opened lower on Tuesday, with the three main indexes in red, but the Dow and the Nasdaq turned into the green. Read more...
Lilly and Incyte Provide Update on Baricitinib
The Best- and Worst-Performing Stocks of the Last Decade The list and observations
In a recent article I shared a list of the 30 best-performing stocks since 1980. One of the readers was kind enough to leave a comment and suggested that I should run the lists of different time periods and compare them to see which companies consistently show up on the list. Read more...
Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results
New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)

Ratios

vs
industry
vs
history
Forward PE Ratio 238.10
INCY's Forward PE Ratio is ranked lower than
99% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. INCY: 238.10 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 22.87
INCY's PB Ratio is ranked lower than
94% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. INCY: 22.87 )
Ranked among companies with meaningful PB Ratio only.
INCY' s PB Ratio Range Over the Past 10 Years
Min: 22.2  Med: 54.8 Max: 391.93
Current: 22.87
22.2
391.93
PS Ratio 17.26
INCY's PS Ratio is ranked lower than
59% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. INCY: 17.26 )
Ranked among companies with meaningful PS Ratio only.
INCY' s PS Ratio Range Over the Past 10 Years
Min: 7.17  Med: 20.91 Max: 239.71
Current: 17.26
7.17
239.71
Price-to-Free-Cash-Flow 494.33
INCY's Price-to-Free-Cash-Flow is ranked lower than
97% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. INCY: 494.33 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
INCY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.24  Med: 200.81 Max: 1045.87
Current: 494.33
7.24
1045.87
Price-to-Operating-Cash-Flow 174.87
INCY's Price-to-Operating-Cash-Flow is ranked lower than
94% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. INCY: 174.87 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INCY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.19  Med: 173.01 Max: 852.8
Current: 174.87
7.19
852.8
EV-to-EBIT -174.69
INCY's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. INCY: -174.69 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8534.9  Med: -10.4 Max: 1569.2
Current: -174.69
-8534.9
1569.2
EV-to-EBITDA -323.92
INCY's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. INCY: -323.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
INCY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1585.6  Med: -9.9 Max: 2618.5
Current: -323.92
-1585.6
2618.5
EV-to-Revenue 17.96
INCY's EV-to-Revenue is ranked lower than
57% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. INCY: 17.96 )
Ranked among companies with meaningful EV-to-Revenue only.
INCY' s EV-to-Revenue Range Over the Past 10 Years
Min: 7.5  Med: 21.7 Max: 273.2
Current: 17.96
7.5
273.2
Current Ratio 2.88
INCY's Current Ratio is ranked lower than
62% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. INCY: 2.88 )
Ranked among companies with meaningful Current Ratio only.
INCY' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.67 Max: 21.14
Current: 2.88
1.51
21.14
Quick Ratio 2.87
INCY's Quick Ratio is ranked lower than
59% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. INCY: 2.87 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s Quick Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.66 Max: 21.14
Current: 2.87
1.51
21.14
Days Inventory 20.66
INCY's Days Inventory is ranked higher than
87% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. INCY: 20.66 )
Ranked among companies with meaningful Days Inventory only.
INCY' s Days Inventory Range Over the Past 10 Years
Min: 14.49  Med: 46.41 Max: 323.15
Current: 20.66
14.49
323.15
Days Sales Outstanding 47.36
INCY's Days Sales Outstanding is ranked higher than
65% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. INCY: 47.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.25  Med: 45.23 Max: 6447.52
Current: 47.36
12.25
6447.52
Days Payable 336.71
INCY's Days Payable is ranked higher than
90% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. INCY: 336.71 )
Ranked among companies with meaningful Days Payable only.
INCY' s Days Payable Range Over the Past 10 Years
Min: 336.71  Med: 2972.25 Max: 32457.1
Current: 336.71
336.71
32457.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
INCY's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. INCY: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INCY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.8  Med: -9.2 Max: -0.6
Current: -5
-17.8
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 101.05
INCY's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. INCY: 101.05 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INCY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.23  Med: 8.54 Max: 3615
Current: 101.05
1.23
3615
Price-to-Tangible-Book 38.40
INCY's Price-to-Tangible-Book is ranked lower than
95% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. INCY: 38.40 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INCY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.91  Med: 6 Max: 340.56
Current: 38.4
0.91
340.56
Price-to-Intrinsic-Value-Projected-FCF 33.19
INCY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
90% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. INCY: 33.19 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
INCY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 9.91  Med: 36.6 Max: 145.06
Current: 33.19
9.91
145.06
Price-to-Median-PS-Value 0.83
INCY's Price-to-Median-PS-Value is ranked higher than
62% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. INCY: 0.83 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INCY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.84 Max: 10.64
Current: 0.83
0.11
10.64
Earnings Yield (Greenblatt) % -0.57
INCY's Earnings Yield (Greenblatt) % is ranked higher than
73% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. INCY: -0.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INCY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -37.7  Med: -2 Max: 1.3
Current: -0.57
-37.7
1.3

More Statistics

Revenue (TTM) (Mil) $1,306.49
EPS (TTM) $ -0.79
Beta1.48
Short Percentage of Float3.44%
52-Week Range $83.01 - 153.15
Shares Outstanding (Mil)210.65

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 1,477 1,710 2,123 2,752
EPS ($) -0.48 0.54 1.37 3.21
EPS without NRI ($) -0.48 0.54 1.37 3.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
59.77%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}